Haziran 17, 2019, 11:16:48 ÖS
Haberler:

De ki: Allah beni ve beraberimdekileri (sizin istediðiniz üzere) yok etse veya (öyle olmayýp da) bizi esirgese, (söyleyin bakalým) inkârcýlarý yakýcý azaptan kurtaracak kimdir? (Mulk -27)

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive

Başlatan Fussilet, Nisan 26, 2009, 05:37:42 ÖS

« önceki - sonraki »

0 Üye ve 1 Ziyaretçi konuyu incelemekte.

Fussilet

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: Outcomes of an expanded access program.

Lung Cancer. 2007 Feb;55(2):187-94. Epub 2006 Nov 7.
Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Janne PA; On Behalf of Pemetrexed Expanded Access Program Investigators.
Eli Lilly and Company, Lilly Corporate Center, Drop Code 6831, Indianapolis, IN 46285, United States.

BACKGROUND: An expanded access program (EAP) provided patient access to pemetrexed prior to its commercial availability. The current report consists of US patients in the EAP who had chemotherapy naive pleural mesothelioma. METHODS: Eligible patients had a histologic or cytologic diagnosis of malignant mesothelioma that was not amenable to curative treatment with surgery. Study treatment consisted of pemetrexed 500mg/m(2) in combination with cisplatin 75mg/m(2) once every 21 days. Vitamin B12, folic acid, and dexamethasone were administered as prophylaxis. Serious adverse events (SAEs) were reported by investigators and compiled in a pharmacovigilance database for all patients enrolled in the EAP. RESULTS: Of 1056 patients receiving at least one dose of pemetrexed in the EAP, 728 had chemotherapy naive pleural mesothelioma. Median age of this group was 70 years (range 23-89 years) and 84% were male. Among 615 patients, overall response rate was 20.5%, including 12 complete responses (2.0%) and 114 partial responses (18.5%). An additional 290 patients (47.2%) had stable disease. Median survival for all 728 patients was 10.8 months (95% CI=9.8, 12.3; 60.3% censorship) and 1 year survival was 45.4%. The most commonly reported SAEs in the overall EAP irrespective of causality were dehydration (7.2%), nausea (5.2%), vomiting (4.9%), dyspnea (3.8%), and pulmonary embolism (2.4%). CONCLUSIONS: In this large cohort, 67.7% of patients treated with first-line chemotherapy experienced a response or stable disease. Survival time and toxicity from this EAP were promising for this difficult-to-treat disease.
içimdeki tüm putlarý kýrdým ve sana yöneldim Rabbim...
Bu geliþimi kabul et, beni benden al, beni sana baðýþla...
-Fussilet-
_____________________________________________
Bugün gam tekkegahýnda feda bir canýmýz vardýr
Gönül abdal-ý aþk olmuþ gelin kurbanýmýz vardýr
Çimende bülbülü gördüm yaman efgan ile söyler
Dili kahhar ile her dem gül-i handanýmýz vardýr


Urfalý Abdi


Oruç nedir?, Orucu Bozan Haller ,  Ramazan Orucu...